Approximately one-third of pediatric patients with refractory convulsive status epilepticus (RSE) develop neurologic deficits, according to findings from a multicenter, prospective, observational study presented at the 2017 American Epilepsy Society Annual Meeting, December 1-5, 2017 in Washington, DC.

A total of 163 pediatric patients with RSE who had ≥1-year follow-up data available were included in this observational analysis. For this study, the primary outcome was comprised of new neurologic deficit developments during follow-up.

At median follow-up of 2.1 years, 142 patients were taking a median of 2 antiseizure medications. Of these patients, 109 continued to have unprovoked seizures. Additionally, 60 of 77 patients who had no prior epilepsy history were administered antiseizure medications during the follow-up period. 

Related Articles

The researchers found that 26 patients presented with additional episodes of RSE at follow-up, whereas a total of 84 patients had a need for rescue therapy at least once. Repeated episodes of RSE occurred in 16 of the 127 patients who had no clinical history of RSE.

During the follow-up period, new neurologic deficits developed in 36 patients. According to findings from a multivariate analysis, the duration of RSE represented the only significant predictor for the development of new neurologic deficits (P =.04). Patients who developed neurologic deficits had a significantly longer duration of RSE compared with those who did not (27.75; 95% CI, 1.75-144 h vs 3.68; 95% CI, 2-13 h, respectively; P =.023).

The investigators concluded that the duration of RSE may provide predictive value for future neurologic issues.

Disclosures: The investigators report financial support from the Pediatric Epilepsy Research Foundation and Epilepsy Research Fund.

Visit MPR‘s conference section for more coverage of AES 2017.


Piantino JA, Gaínza-Lein M, Chapman K, et al. Long-term outcomes in pediatric refractory status epilepticus (The Pserg Cohort). Presented at: 2017 American Epilepsy Society Annual Meeting. December 1-5, 2017; Washington, DC. Abstract 1.214.

This article originally appeared on Neurology Advisor